Author of

• 30292

  +

  EP1.01 - Advanced NSCLC (ID 150)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 30398

    +

    EP1.01-95 - Up-Regulation of c-Met by Cox-2 Promotes Resistance of Gefitinib in NSCLC Patients (ID 3049)

    08:00 - 18:00  |  Presenting Author(s): Fei Wang
    • Abstract
    • Slides

    Background
    

    c-Met amplification is one of the reasons for Gefitinib resistance in NSCLC patients.

    Method
    

    1.Explore the mechanism of the up-regulation of c-Met by Cox-2; 2.Combination of Cox-2 inhibitor and Gefitinib can overcome Gefitinib resistance in cells or animal study; 3.Test the expression pattern or activity of Cox-2 in NSCLC patients, and evaluate the possibility of Cox-2 serving as biomarker for Gefitinib resistance and prognosis for NSCLC patients.

    Result
    

    1.Both c-met and Cox-2 are highly expressed in Gefitinib resistant lung cancer cell lines; 2.Cox-2 is highly expressed in malignant lung adenocarcinoma than in matched normal tissues; 3.Inhibition of Cox-2 can decrease c-Met expression， and promote apoptosis induced by Gefitinib in Gefitinib resistant cells.

    Conclusion
    

    Up-regulation of c-Met by Cox-2 promotes resistance of Gefitinib in NSCLC patients

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.